Listed by the USPTO as ALFANO, ALAN
Tech Center 1600 • Art Units: 1641 1646
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18353981 | CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF | Final Rejection | Sanofi |
| 18261950 | ACTINOHIVIN VARIANT POLYPEPTIDES AND RELATED METHODS | Non-Final OA | University of Louisville Research Foundation, Inc. |
| 18277594 | ANTIBODIES | Non-Final OA | UCB BIOPHARMA SRL |
| 17907116 | AUTONOMOUS KNOB DOMAIN PEPTIDES | Final Rejection | UCB BIOPHARMA SRL |
| 18557875 | CD99-targeting chimeric antigen receptor and application thereof | Non-Final OA | WUHAN BIO-RAID BIOTECH CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your StrategyAlan Alfano examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
